Another randomized, placebo-controlled study found low-dose IL-2 to elicit a reduction in SLE activity according to the SLEDAI score, which was also associated with a reduction in anti-dsDNA antibody titers [110]. The gene discussed is IL2; the disease is systemic lupus erythematosus.